Interaction between microbiota and immunity in health and disease.
Danping Zheng, Timur Liwinski, Eran Elinav
https://pubmed.ncbi.nlm.nih.gov/32433595/Actively Recruiting
Led by University Hospital of North Norway · Updated on 2026-08-14
99
Participants Needed
1
Research Sites
26 weeks
Total Duration
Researchers are evaluating fecal microbiota transplantation FMT as a treatment for axial spondyloarthritis axSpA, a chronic inflammatory disease affecting the spine and sacroiliac joints. This study focuses on patients with axSpA who have had an inadequate response to biologic therapies. The trial aims to see if FMT can reduce disease activity, relieve pain and fatigue, and restore the normal gut microbiota balance in these patients. Participants will be randomly assigned to receive a single enema treatment containing either feces from a healthy donor donor FMT or their own feces placebo. The fecal matter is combined with glycerol and saline to a total volume of 440 ml. The primary evaluation will take place 90 days after treatment, with continued monitoring of efficacy and safety for one year. This study uses a double-blind design to compare donor versus autologous FMT. During the study, participants will undergo multiple assessments including disease activity scores, pain and fatigue scales, physical function indexes, and quality-of-life questionnaires at baseline and several time points up to 365 days. Researchers will monitor adverse events and measure clinical improvements, focusing on the initiation of immunomodulatory treatment within 90 and 365 days. Participants will be followed closely to track treatment effects and safety throughout the one-year period.
CONDITIONS
Fecal Microbiota Transplantation in Axial Spondyloarthritis
G
Gunnstein Bakland, MD PhD
P
Peter Johnsen, MD PhD
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here
University Hospital of North Norway
Lead Sponsor
Helse Nord
Collaborating Sponsor
You may qualify if you...
You will not qualify if you...
Duration - 2 to 4 weeks
Participants are screened for eligibility to participate in the trial.
1 visit (in-person)
Duration - 1 day
Participants receive a single enema containing feces from either a healthy donor or their own stool as placebo.
1 visit (in-person at baseline)
Duration - 365 days
Participants are monitored for efficacy and safety with assessments at multiple time points up to 365 days after treatment.
Multiple visits at baseline, day 30, day 60, day 90, day 180, day 270, and day 365
Study Type
INTERVENTIONAL
Masking
QUADRUPLE
Allocation
RANDOMIZED
Model
PARALLEL
Primary Purpose
TREATMENT
Number of Arms
4
Have more questions? Get in touch with our team for quick support
Danping Zheng, Timur Liwinski, Eran Elinav
https://pubmed.ncbi.nlm.nih.gov/32433595/Peter Holger Johnsen, Frank Hilpüsch, Jorunn Pauline Cavanagh...
https://pubmed.ncbi.nlm.nih.gov/29100842/Xenofon Baraliakos, Juergen Braun
https://pubmed.ncbi.nlm.nih.gov/22265264/Maxime Breban, Marie Beaufrère, Simon Glatigny
https://pubmed.ncbi.nlm.nih.gov/32173258/Aamer Imdad, Maribeth R Nicholson, Emily E Tanner-Smith...
https://pubmed.ncbi.nlm.nih.gov/30480772/Thomas Bazin, Katarzyna B Hooks, Thomas Barnetche...
https://pubmed.ncbi.nlm.nih.gov/29615661/University Hospital of North Norway
Lead Sponsor
Helse Nord
Collaborating Sponsor